BH
Bengt Hallberg

Elite Scholar

161
Works
7,205
Citations
47
H-Index
Search Authors
Author Statistics
External Links
OpenAlex Profile ORCID Profile

Bengt Hallberg

Also known as: B Hallberg, B. Hallberg, Bengt HALLBERG, Bengt Hallberg

161

Total Works

7,205

Citations

47

H-Index

88

i10-Index

Citation & Works Trend by Year
34 years active
Top Research Topics
Neuroblastoma Research and Treatments (94) Lung Cancer Treatments and Mutations (74) Neurofibromatosis and Schwannoma Cases (71) Protein Kinase Regulation and GTPase Signaling (27) Cancer Genomics and Diagnostics (27)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells iScience 0
2026 Novel activating SNRNP70-ALK fusion in congenital infant-type hemispheric glioma displays clinical response to lorlatinib: a case-report npj Precision Oncology 2
2025 ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCN bioRxiv (Cold Spring Harbor Laboratory) 1
2025 Supplementary information from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Figure S2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Figure S1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Figure S4 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Supplementary data 1 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Supplementary data 3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Supplementary data 2 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2025 Figure S3 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2024 RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastoma bioRxiv (Cold Spring Harbor Laboratory) 0
2024 Data from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2024 Figure 6 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0
2024 Figure 5 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis 0

Data source: OpenAlex API